<DOC>
	<DOCNO>NCT00004088</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Biological therapy , interferon alfa , use different way stimulate immune system stop cancer cell grow . Thalidomide may stop growth cancer cell stop blood flow tumor . Pamidronate may help reduce side effect treatment multiple myeloma . PURPOSE : This phase II trial study combination chemotherapy , peripheral stem cell transplantation , biological therapy , pamidronate , thalidomide see well work treat patient stage I , stage II , stage III multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy , Peripheral Stem Cell Transplantation , Biological Therapy , Pamidronate Thalidomide Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility toxic effect high-dose melphalan , busulfan , cyclophosphamide follow autologous peripheral blood stem cell rescue , interferon alfa , pamidronate patient responsive stable , low-bulk multiple myeloma . - Determine response rate progression-free overall survival patient treat regimen . - Determine feasibility add thalidomide interferon alfa pamidronate patient complete remission ( CR ) 6 month second course high-dose chemotherapy . - Determine whether administration thalidomide increase CR rate patient CR 6 month second course high-dose chemotherapy determine effect progression-free overall survival patient . - Determine pharmacokinetics busulfan cyclophosphamide correlate pharmacokinetics toxic effect drug outcome patient . - Determine effect thalidomide microvascular density bone marrow correlate possible effect outcome patient . - Determine cytogenetics , gene rearrangement , fluorescence situ hybridization baseline post treatment bone marrow blood specimen correlate presence/persistence feature treatment outcome patient . OUTLINE : Patients receive cyclophosphamide IV 2 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) IV twice day begin day 2 continue peripheral blood stem cell ( PBSCs ) collect . PBSCs collect begin day 10 . Patients receive high-dose melphalan IV day -1 . PBSCs reinfused day 0 . G-CSF administer IV SC daily begin day 1 continue blood count recover . Between 8 14 week later , patient receive high-dose busulfan IV every 6 hour day -7 -4 cyclophosphamide IV 2 hour day -3 -2 . PBSCs reinfused day 0 G-CSF administer IV SC daily blood count recover . Patients respond stable disease chemotherapy receive maintenance therapy interferon alfa begin 14-20 week day 0 second course chemotherapy . Interferon alfa administer SC 3 time week 3 year . Patients also receive pamidronate IV every 4 week disease progression . Patients complete remission ( CR ) 6 month complete second course chemotherapy receive oral thalidomide daily maximum 1 year 3 month achieve CR . Patients follow monthly 1 year , every 3 month 1 year , periodically thereafter . PROJECTED ACCRUAL : A total 70 patient accrue study within approximately 2.5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Pamidronate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIII multiple myeloma Less 18 month since diagnosis Smoldering myeloma allow evidence progressive disease require therapy At least 25 % increase M protein level Bence Jones excretion Hemoglobin great 10.5 g/dL Hypercalcemia Frequent infection Rise serum creatinine normal 2 separate occasion Nonquantifiable monoclonal protein allow criterion multiple myeloma smolder myeloma meet Response/status induction therapy : Responding stable disease AND great 40 % myelomatous involvement bone marrow No Waldenstrom 's macroglobulinemia PATIENT CHARACTERISTICS : Age : 65 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT less 2.5 time upper limit normal Hepatitis B antigen hepatitis C RNA negative Renal : See Disease Characteristics Creatinine great 1.4 mg/dL Creatinine clearance great 65 mL/min Cardiovascular : Cardiac ejection fraction least 50 % MUGA echocardiogram Pulmonary : FEV_1 great 60 % DLCO great 50 % predict low limit Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception HIV negative No medical psychosocial problem would increase patient risk No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix No known hypersensitivity filgrastim ( GCSF ) E. coliderived protein PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 3 prior chemotherapy regimen At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>